Tools
Mandible Osteoradionecrosis
Introduction
Osteoradionecrosis (ORN) of the mandible is a severe iatrogenic condition characterized by loss of bone viability in areas of the mandible following radiation exposure, most commonly after radiation therapy for oral or oropharyngeal cancers. ORN is a state of injured bone tissue with inadequate healing or remodeling response persisting for at least 3 to 6 months. The condition may develop following radiation therapy or local trauma to irradiated bone, as in dental extractions performed after radiation therapy. ORN is a distinct clinical entity from primary osteomyelitis or persistent or recurrent malignancy, although clinical presentation may resemble both conditions. No universally accepted pathophysiologic description exists. However, relative tissue hypoxia and free radical–mediated injury are widely cited mechanisms and form the basis of most treatment strategies.[1][2][3][4]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Radiation exposure causes DNA damage and inhibition of mitosis. Radiotherapy induces injury in both malignant and normal cells, with the greatest impact on rapidly dividing cell populations. Tumor cells often demonstrate higher mitotic rates compared with nontumor cells, resulting in preferential radiation sensitivity. Normal tissues with rapid cellular turnover are also susceptible to radiation injury.
Squamous epithelial cells exhibit high turnover and marked radiosensitivity, contributing to radiation-induced mucositis and dermatitis. Skin and mucous membranes possess a relatively robust and redundant vascular supply, supporting recovery over time. Bone and cartilage demonstrate more limited vascularity, contributing to a more protracted or arrested healing response following injury. Bone healing depends on coordinated osteoclast and osteoblast activity, and disruption of this process is a proposed mechanism driving ORN. Radiotherapy also induces progressive endarteritis affecting large- and medium-caliber vessels and impairs capillary regrowth required for normal tissue repair. Radiation-induced reduction in tissue perfusion within exposed regions contributes to chronic, nonhealing wounds characteristic of ORN.[5] Loss of cellularity combined with impaired reparative capacity further limits bone regeneration, resulting in persistent tissue breakdown.
Current pathophysiologic understanding integrates 3 major mechanisms proposed since the 1980s, including hypoxic–hypocellular–hypovascular change, radiation-induced fibroatrophy, and radiation-induced osteomyelitis. Each theory is discussed in subsequent sections of this article.[6][7][8][9]
Epidemiology
Contemporary estimates place the incidence of ORN at approximately 3%, although rates vary with radiation dose, delivery technique, and diagnostic criteria.[10] The condition presents 2 to 4 years after completion of radiation therapy on average. A subset of patients develop persistent nonhealing wounds at the primary tumor site, commonly involving the mandible and larynx, which appear immediately after radiation therapy and may progress to ORN or chondroradionecrosis.[11]
Incidence is strongly influenced by radiation dose, with higher total doses associated with increased risk of ORN. Rates remain low at total doses below 60 Gy and rise substantially between 60 and 70 Gy, with 70 Gy frequently used in head and neck cancer treatment.[12] Mechanical injury after the initiation of radiotherapy also increases the risk of ORN. In the mandible, this pattern is commonly observed following completion of radiation therapy when dental implants are placed for rehabilitation or when teeth are extracted for primary dental pathology.[13] Consequently, ORN may occur years after radiotherapy, either as a spontaneous or trauma-induced process.
Pathophysiology
The precise pathophysiology of ORN remains under active debate and scholarly inquiry, but no single unifying mechanism has been established. Modern understanding of the condition integrates several prominent proposed mechanisms into a composite framework.
The 3H (hypoxic–hypocellular–hypovascular) theory was first proposed in 1983 by Marx and postulates that ORN results from a sequence of injury events, beginning with radiation exposure, and may be exacerbated by subsequent trauma to affected tissues. The radiated mandible and surrounding tissues develop hyperemia, inflammation, and obliterative endarteritis. Small vessels become thrombosed, producing hypovascular, hypocellular, hypoxic tissue that undergoes progressive breakdown. Rates of cell death and collagen lysis exceed the homeostatic balance between cellular replacement and collagen synthesis. Impaired reparative capacity leads to further reduction in vascularity and oxygen delivery. The overall outcome is a chronic, aseptic, nonhealing wound. The Marx model posits that acquired hypovascularity and hypoperfusion drive nonhealing and form the rationale for hyperbaric oxygen therapy (HBOT).
The radiation-induced fibroatrophy theory was proposed by Delanian in 2004 and posits that radiation fundamentally alters and ultimately impairs the cellular healing response through generation of free radical species. The presence of free radicals leads to fibroblast dysregulation via a chronic inflammatory response, resulting in abnormal tissue repair. The resulting fibrous scar tissue, described as "fibrous atrophy," is disorganized due to dysregulated fibroblast activity. Initially damaged bone and surrounding tissue is replaced by disordered fibrous scar tissue that is relatively fragile and hypoperfused. Fibrotic tissue demonstrates susceptibility to breakdown under minor mechanical stress, producing nonhealing wounds. This framework supports antifibrotic and antioxidant-based treatment strategies, including the PENTO protocol, which combines pentoxifylline and vitamin E and is widely used in contemporary practice.[14][15][16]
The radiation-induced osteomyelitis theory is cited largely for historical context, as most modern scholars do not consider it an etiologic cause of ORN but rather a potential manifestation. The theory suggests that radiation compromises the bone–mucosal barrier, allowing bacterial entry from the subgingival pocket or traumatized mucosa, with subsequent infection contributing to progressive bone destruction.[17] First proposed by Meyer in 1970, the model framed ORN as a subset of osteomyelitis based on loss of barrier integrity and subsequent bacterial invasion of bone. Modern interpretations regard ORN as a distinct entity, although shared risk factors for progression, including hypovascularity, hypoxia, and fragile tissue architecture, also predispose to osteomyelitis, and both conditions frequently coexist.[18][19][20]
Toxicokinetics
ORN is rarely reported at a total radiation dose below 60 Gy delivered over 6 weeks. The incidence increases with higher dose ranges, reaching 1.8% at 60 to 70 Gy and 9% at doses exceeding 70 Gy delivered over 7 weeks. As most head and neck malignancies are treated to a cumulative dose of approximately 70 Gy over 6 weeks, patients with oral or oropharyngeal cancers are the highest-risk population for development of ORN.[12]
History and Physical
The most common complaint is a painful, nonhealing oral lesion. The manifestations may include a persistent oral ulcer despite treatment, odynophagia, pain-related trismus, occlusal changes, a foreign body sensation in the oral cavity, or expectoration of bone fragments. Malodor complaints, including halitosis, may occasionally present as the initial symptom.
A detailed oncologic history is essential, including primary tumor site and stage, dates of radiation and chemotherapy initiation and completion, and any prior surgical interventions. Dental history requires careful documentation, including preradiation dental care and any postradiation procedures, such as cleanings, implants, dentures, or obturators.
Oral cavity examination may demonstrate an obvious lesion or only granulation tissue. Flexible laryngoscopy is indicated to assess the larynx and posterior mandible with its mucosal coverage, particularly in the presence of odynophagia. Dental examination is warranted when dentition is present, as loose teeth and periodontal disease may indicate underlying ORN.
Suspicious lesions or granulation tissue require biopsy to exclude persistent or recurrent malignancy prior to the initiation of ORN-directed management. A thorough neck examination is required to evaluate for masses or lymphadenopathy suggestive of recurrent disease.
Evaluation
ORN of the jaw is operationally characterized by a radiographic lytic or mixed sclerotic bone lesion occurring within a previously irradiated anatomic site, visibly exposed bone, bone that can be probed through a periodontal pocket or fistula, or the presence of a pathologic fracture.[21] Evaluation should include review of radiotherapy and dental records, with particular attention to treatment modality, radiation field, and cumulative radiation dose. Any visible wound requires biopsy to exclude persistent or recurrent primary malignancy or the development of a secondary malignancy.[22][23][24]
Imaging studies assist in establishing the diagnosis and determining disease extent. Panoramic radiography (orthopantomography) serves as a useful screening modality but may underestimate lesion severity. Radiographic findings may include lytic areas with ill-defined, nonsclerotic borders. Computed tomography (CT) of the mandible is indicated when orthopantomographic findings are inconclusive or when more detailed assessment is required. CT may demonstrate cortical bone disruption, mixed lytic and sclerotic changes, and pathologic fractures.
Treatment / Management
Prevention of ORN is of paramount importance. Optimization of dental health before therapeutic radiation reduces the risk of odontogenic complications and subsequent ORN.
Management strategies can be broadly divided into preradiotherapy prevention and postdiagnosis rehabilitation. Treatment options include dental, medical, surgical, and hyperbaric modalities.[25][26][27](B2)
Preradiotherapy management requires comprehensive dental evaluation and treatment by a clinician experienced in head and neck oncology. Assessment should include full-mouth radiography, dental and periodontal evaluation, and extraction of teeth with a poor prognosis. Tooth extraction should ideally be completed at least 2 weeks before initiation of radiotherapy. Optimal oral health is associated with reduced ORN risk. Dental prophylaxis and ongoing oral care should continue before, during, and after radiotherapy. Medical therapy has a limited role in prevention and management. Adequate nutrition and saline irrigation may help control oral mucositis. Antibiotic therapy is indicated only in the presence of confirmed secondary infection. Pentoxifylline, an anti-inflammatory and vasodilatory agent, has demonstrated utility in the management of soft-tissue injury and preservation of salivary gland function. This agent is combined with vitamin E as part of the PENTO or PENTOCLO (pentoxifylline, tocopherol, and clodronate) protocols.[28][29]
Treatment of established ORN frequently requires surgical intervention with removal of nonviable bone.[30][31] Debridement or sequestrectomy of devitalized bone is often the initial surgical approach, with resection carried down to healthy, bleeding bone. Local flap advancement may provide adequate coverage, depending on the location and condition of surrounding tissues. Failure of local reconstruction may necessitate regional or free tissue transfer to introduce healthy, nonirradiated tissue and preserve remaining bone.[32] Segmental mandibulectomy with vascularized bone flap reconstruction may be required when conservative surgical measures are unsuccessful.[33](A1)
HBOT can help promote healing before surgery or serve as an adjunct to surgical management, although evidence supporting HBOT as a standalone treatment remains limited and controversial.[34] HBOT may also be used prophylactically before planned surgery or tooth extraction within tissue exposed to radiation doses exceeding 60 Gy. The therapeutic rationale for HBOT is promotion of angiogenesis within hypoxic tissue, thereby enhancing conditions for repair. Standard HBOT protocols typically include 30 preoperative and 10 postoperative treatments. The treatments are administered at 2.0 to 2.5 atm for 90 to 120 minutes once daily, 5 days per week. Subsequent surgical management is determined by ORN severity.
Differential Diagnosis
Several conditions should be considered in the differential diagnosis of ORN because clinical and radiographic findings may overlap with those of odontogenic, inflammatory, and neoplastic processes. These conditions include calcifying epithelial odontogenic tumor, odontomas, periapical abscesses, periapical granulomas, rarefying or condensing osteitis, and recurrent malignancy. Accurate diagnosis is essential because management strategies differ substantially, and failure to identify an alternative diagnosis may result in delayed treatment, inappropriate intervention, or progression of underlying disease.
Pertinent Studies and Ongoing Trials
Current advances in both medical and surgical management of mandibular ORN may alter the role of HBOT. Combination therapy using PENTO or PENTOCLO has shown clinical promise. However, large confirmatory studies have not demonstrated HBOT to be clearly superior to these newer pharmacological approaches. PENTO and PENTOCLO carry a small risk of bisphosphonate-related osteonecrosis of the jaw (BRONJ).[35]
A 2022 randomized controlled study of patients with mandibular ORN requiring surgical intervention (n = 65) reported a 70% healing rate in the HBOT group versus 51% in the control group. The number needed to treat with HBOT to prevent treatment failure was 5. However, the study was underpowered and limited definitive conclusions regarding efficacy.[36]
Treatment Planning
Dental evaluation prior to initiation of radiation therapy can reduce the risk of subsequent ORN. Routine preradiotherapy dental assessment should be undertaken in all patients planned for head and neck irradiation.
Staging
The Marx staging is the most commonly used system for classifying ORN and is based primarily on response to HBOT. Stage 1 is characterized by exposed alveolar bone without pathologic fracture, with clinical response to HBOT and minor bony debridement. Stage 2 includes cases that fail to respond to 30 daily HBOT sessions combined with minor debridement. This stage also includes cases that initially require major debridement. Management typically involves more extensive surgical debridement, followed by an additional 10 postoperative HBOT sessions. Stage 3 represents failure of stage 1 or stage 2 management. This stage may also present initially with advanced disease features, including pathologic fracture, orocutaneous fistula formation, or radiographic evidence of lytic involvement of the inferior mandibular border.[37]
Pearls and Other Issues
Unavoidable postradiotherapy extractions require careful planning and management. ORN risk, comparable to that associated with preradiotherapy extractions, may be reduced with HBOT before and after extraction. The protocol consists of 20 pre-extraction treatments and 10 postextraction treatments delivered at 2.4 atmospheres for 90 minutes per session, administered once daily, 5 days per week.
BRONJ is a distinct entity that shares clinical similarities with ORN of the mandible. BRONJ is associated with bisphosphonate exposure, often in combination with trauma to dentoalveolar tissues. Both conditions result in chronic, poorly healing osseous defects. Differentiation relies on clinical history and imaging findings. ORN is associated with prior radiation exposure and typically demonstrates osteolytic lesions on CT imaging. BRONJ is associated with bisphosphonate exposure and more commonly demonstrates osteosclerotic changes on CT imaging. Accurate distinction is essential because management strategies differ substantially. BRONJ is more likely to respond to medical therapy with limited surgical intervention, whereas ORN is primarily managed surgically.
Caution is required to differentiate ORN from recurrent malignancy due to overlapping clinical and radiographic features. Development of such findings within 6 months of completion of radiation therapy raises concern for persistent or recurrent malignancy.[38]
Enhancing Healthcare Team Outcomes
Diagnosis and management of ORN are optimally conducted through an interprofessional team approach involving a dentist, surgeon, pharmacist, hyperbaric medicine specialist, and nurse. Prevention of ORN is of critical importance. Accordingly, management is conceptually divided into preradiotherapy prevention and posttreatment rehabilitation. ORN may be managed through dental, medical, surgical, and HBOT-based approaches.
Preradiotherapy care for patients undergoing oral cavity irradiation requires comprehensive dental evaluation and management by a dentist experienced in head and neck oncology. Pretreatment assessment should include full-mouth radiography, dental and periodontal evaluation, and extraction of teeth with poor prognosis. Medical therapy plays a limited role in ORN prevention and management. Supportive measures, including adequate nutrition and saline irrigation, assist in the management of oral mucositis.
Treatment of diagnosed ORN typically requires surgical intervention with removal of nonviable bone. In selected cases, HBOT may be used prophylactically for planned surgery or tooth extraction in tissues exposed to radiation doses exceeding 60 Gy. HBOT is intended to promote angiogenesis within hypoxic tissue, thereby improving conditions for wound repair.
Prognosis in ORN is generally guarded and depends on disease severity, anatomical location, and overall patient medical and dental status. Persistent or recurrent malignancy must be excluded prior to initiation of ORN-directed therapy.[39]
References
Renda L, Tsai TY, Huang JJ, Ito R, Hsieh WC, Kao HK, Hung SY, Huang Y, Huang YC, Chang YL, Cheng MH, Chang KP. A nomogram to predict osteoradionecrosis in oral cancer after marginal mandibulectomy and radiotherapy. The Laryngoscope. 2020 Jan:130(1):101-107. doi: 10.1002/lary.27870. Epub 2019 Feb 20 [PubMed PMID: 30786034]
Toledano-Serrabona J, Párraga-Manzol G, Sánchez-Garcés MÁ, Gay-Escoda C. Osteoradionecrosis of the jaws triggered by dental implants placement: A case report. Journal of clinical and experimental dentistry. 2019 Jan:11(1):e91-e96. doi: 10.4317/jced.55326. Epub 2019 Jan 1 [PubMed PMID: 30697400]
Level 3 (low-level) evidenceStranix JT, Stern CS, Rensberger M, Ganly I, Boyle JO, Allen RJ Jr, Disa JJ, Mehrara BJ, Garfein ES, Matros E. A Virtual Surgical Planning Algorithm for Delayed Maxillomandibular Reconstruction. Plastic and reconstructive surgery. 2019 Apr:143(4):1197-1206. doi: 10.1097/PRS.0000000000005452. Epub [PubMed PMID: 30676509]
Feng Z, Wang C, Li B, Kim K, Li J, Mao M, Qin L, Li H, Han Z. A pilot study of modified resection for anterior floor of the mouth squamous cell carcinoma without infiltration of the mandible. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery. 2019 Mar:47(3):516-522. doi: 10.1016/j.jcms.2018.11.019. Epub 2018 Nov 28 [PubMed PMID: 30638742]
Level 2 (mid-level) evidenceYan T, Zhang T, Mu W, Qi Y, Guo S, Hu N, Zhao W, Zhang S, Wang Q, Shi L, Liu L. Ionizing radiation induces BH(4) deficiency by downregulating GTP-cyclohydrolase 1, a novel target for preventing and treating radiation enteritis. Biochemical pharmacology. 2020 Oct:180():114102. doi: 10.1016/j.bcp.2020.114102. Epub 2020 Jun 17 [PubMed PMID: 32562786]
Level 2 (mid-level) evidenceManimaran K, Sankaranarayanan S, Ravi VR, Elangovan S, Chandramohan M, Perumal SM. Treatment of osteoradionecrosis of mandible with bone marrow concentrate and with dental pulp stem cells. Annals of maxillofacial surgery. 2014 Jul-Dec:4(2):189-92. doi: 10.4103/2231-0746.147130. Epub [PubMed PMID: 25593871]
Korambayil PM, Ambookan PV, Pillai S, Karangath RR, George D. Role of Hyperbaric Medicine for Osteoradionecrosis and Post Irradiation Wounds: an Institutional Experience. Indian journal of surgical oncology. 2020 Sep:11(3):469-474. doi: 10.1007/s13193-020-01128-0. Epub 2020 Jun 15 [PubMed PMID: 33013130]
Lyons A, Ghazali N. Osteoradionecrosis of the jaws: current understanding of its pathophysiology and treatment. The British journal of oral & maxillofacial surgery. 2008 Dec:46(8):653-60. doi: 10.1016/j.bjoms.2008.04.006. Epub 2008 Jun 17 [PubMed PMID: 18562055]
Level 3 (low-level) evidenceKumar S, Chandran C, Chacko R, Jesija JS, Paul A. Osteoradionecrosis of Jaw: An Institutional Experience. Contemporary clinical dentistry. 2018 Apr-Jun:9(2):242-248. doi: 10.4103/ccd.ccd_843_17. Epub [PubMed PMID: 29875568]
Yang F, Dee EC, Singh A, Wu Y, Suggitt JO, Treechairusame T, Silverio Polanco E, Honawar A, Zhang Z, Mah D, Sine K, Shim A, Lin H, Kang JJ, Tsai CJ, McBride SM, Riaz N, Gelblum DY, Zakeri K, Chen L, Shamseddine A, Yu Y, Huryn JM, Yom SK, Cracchiolo J, Ganly I, Cohen MA, Sherman EJ, Ho AL, Wong RJ, Estilo CL, Lee NY. Osteoradionecrosis After Intensity-Modulated Radiation Therapy or Proton Therapy in Oropharyngeal Carcinoma. JAMA otolaryngology-- head & neck surgery. 2026 Feb 1:152(2):135-143. doi: 10.1001/jamaoto.2025.4179. Epub [PubMed PMID: 41296362]
Nadella KR, Kodali RM, Guttikonda LK, Jonnalagadda A. Osteoradionecrosis of the Jaws: Clinico-Therapeutic Management: A Literature Review and Update. Journal of maxillofacial and oral surgery. 2015 Dec:14(4):891-901. doi: 10.1007/s12663-015-0762-9. Epub 2015 Mar 10 [PubMed PMID: 26604460]
Iqbal Z, Kyzas P. Analysis of the critical dose of radiation therapy in the incidence of Osteoradionecrosis in head and neck cancer patients: a case series. BDJ open. 2020:6():18. doi: 10.1038/s41405-020-00044-3. Epub 2020 Sep 24 [PubMed PMID: 33042578]
Level 2 (mid-level) evidenceLajolo C, Rupe C, Gioco G, Troiano G, Patini R, Petruzzi M, Micciche' F, Giuliani M. Osteoradionecrosis of the Jaws Due to Teeth Extractions during and after Radiotherapy: A Systematic Review. Cancers. 2021 Nov 18:13(22):. doi: 10.3390/cancers13225798. Epub 2021 Nov 18 [PubMed PMID: 34830954]
Level 1 (high-level) evidenceSharif KF, Baik FM, Yue LE, Qazi M, Brandwein-Weber M, Khorsandi AS, Urken ML. Osteoradionecrosis of the hyoid bone complicated by pharyngocutaneous fistula: A case report and literature review. American journal of otolaryngology. 2019 Mar-Apr:40(2):314-318. doi: 10.1016/j.amjoto.2018.12.006. Epub 2018 Dec 7 [PubMed PMID: 30558897]
Level 3 (low-level) evidenceDekker H, Bravenboer N, van Dijk D, Bloemena E, Rietveld DHF, Ten Bruggenkate CM, Schulten EAJM. The irradiated human mandible: A quantitative study on bone vascularity. Oral oncology. 2018 Dec:87():126-130. doi: 10.1016/j.oraloncology.2018.10.030. Epub 2018 Nov 2 [PubMed PMID: 30527227]
Raggio BS, Winters R. Modern management of osteoradionecrosis. Current opinion in otolaryngology & head and neck surgery. 2018 Aug:26(4):254-259. doi: 10.1097/MOO.0000000000000459. Epub [PubMed PMID: 29727306]
Level 3 (low-level) evidenceSingh A, Huryn JM, Kronstadt KL, Yom SK, Randazzo JR, Estilo CL. Osteoradionecrosis of the jaw: A mini review. Frontiers in oral health. 2022:3():980786. doi: 10.3389/froh.2022.980786. Epub 2022 Jul 28 [PubMed PMID: 35967463]
Aas JA, Reime L, Pedersen K, Eribe ER, Abesha-Belay E, Støre G, Olsen I. Osteoradionecrosis contains a wide variety of cultivable and non-cultivable bacteria. Journal of oral microbiology. 2010 Jul 13:2():. doi: 10.3402/jom.v2i0.5072. Epub 2010 Jul 13 [PubMed PMID: 21523230]
Toshima H, Ogura I. Assessment of inflammatory jaw pathologies using bone SPECT/CT maximum standardized uptake value. Dento maxillo facial radiology. 2020 Dec 1:49(8):20200043. doi: 10.1259/dmfr.20200043. Epub 2020 Jun 15 [PubMed PMID: 32491931]
Godart GA, Elwasila SM, Durvasula RV. A rare case of candida osteomyelitis of the mandible associated with osteoradionecrosis and biofilm formation. IDCases. 2024:37():e02029. doi: 10.1016/j.idcr.2024.e02029. Epub 2024 Jul 18 [PubMed PMID: 39155946]
Level 3 (low-level) evidencePeterson DE, Koyfman SA, Yarom N, Lynggaard CD, Ismaila N, Forner LE, Fuller CD, Mowery YM, Murphy BA, Watson E, Yang DH, Alajbeg I, Bossi P, Fritz M, Futran ND, Gelblum DY, King E, Ruggiero S, Smith DK, Villa A, Wu JS, Saunders D. Prevention and Management of Osteoradionecrosis in Patients With Head and Neck Cancer Treated With Radiation Therapy: ISOO-MASCC-ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024 Jun 1:42(16):1975-1996. doi: 10.1200/JCO.23.02750. Epub 2024 May 1 [PubMed PMID: 38691821]
Liu Z, Cao Y, Ma C, Sun J, Zhang C, He Y. Nomogram model to predict postoperative relapse after mandibular osteoradionecrosis surgery. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery. 2018 Nov:46(11):1960-1967. doi: 10.1016/j.jcms.2018.08.010. Epub 2018 Aug 24 [PubMed PMID: 30249484]
van de Meent MM, Pichardo SEC, Rodrigues MF, Verbist BM, van Merkesteyn JPR. Radiographic characteristics of chronic diffuse sclerosing osteomyelitis/tendoperiostitis of the mandible: A comparison with chronic suppurative osteomyelitis and osteoradionecrosis. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery. 2018 Sep:46(9):1631-1636. doi: 10.1016/j.jcms.2018.06.015. Epub 2018 Jun 30 [PubMed PMID: 30017711]
Menapace DC, Van Abel KM, Jackson RS, Moore EJ. Primary vs Secondary Endosseous Implantation After Fibular Free Tissue Reconstruction of the Mandible for Osteoradionecrosis. JAMA facial plastic surgery. 2018 Sep 1:20(5):401-408. doi: 10.1001/jamafacial.2018.0263. Epub [PubMed PMID: 29801119]
Silvestre-Rangil J, Silvestre FJ. Clinico-therapeutic management of osteoradionecrosis: a literature review and update. Medicina oral, patologia oral y cirugia bucal. 2011 Nov 1:16(7):e900-4 [PubMed PMID: 21743407]
Chaine A, Pitak-Arnnop P, Hivelin M, Dhanuthai K, Bertrand JC, Bertolus C. Postoperative complications of fibular free flaps in mandibular reconstruction: an analysis of 25 consecutive cases. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2009 Oct:108(4):488-95. doi: 10.1016/j.tripleo.2009.05.043. Epub 2009 Aug 20 [PubMed PMID: 19699114]
Level 2 (mid-level) evidenceTeng MS, Futran ND. Osteoradionecrosis of the mandible. Current opinion in otolaryngology & head and neck surgery. 2005 Aug:13(4):217-21 [PubMed PMID: 16012245]
Level 3 (low-level) evidenceAggarwal K, Goutam M, Singh M, Kharat N, Singh V, Vyas S, Singh HP. Prophylactic Use of Pentoxifylline and Tocopherol in Patients Undergoing Dental Extractions Following Radiotherapy for Head and Neck Cancer. Nigerian journal of surgery : official publication of the Nigerian Surgical Research Society. 2017 Jul-Dec:23(2):130-133. doi: 10.4103/njs.NJS_40_16. Epub [PubMed PMID: 29089739]
Vahidi N, Lee TS, Daggumati S, Shokri T, Wang W, Ducic Y. Osteoradionecrosis of the Midface and Mandible: Pathogenesis and Management. Seminars in plastic surgery. 2020 Nov:34(4):232-244. doi: 10.1055/s-0040-1721759. Epub 2020 Dec 24 [PubMed PMID: 33380908]
Geçkil N. Treatment approaches in cases of mandibular osteoradionecrosis: A systematic meta-analysis. Journal of stomatology, oral and maxillofacial surgery. 2025 Jun:126(3S):102316. doi: 10.1016/j.jormas.2025.102316. Epub 2025 Mar 15 [PubMed PMID: 40097107]
Level 1 (high-level) evidenceYin Y, Zeng W, Jing W, Tang W, Guo WH. Evaluation of hyperbaric oxygen therapy for the osteoradionecrosis of the jaws: Meta-analysis. Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology. 2021 Dec 1:39(6):690-697. doi: 10.7518/hxkq.2021.06.010. Epub [PubMed PMID: 34859629]
Level 1 (high-level) evidenceHaffey T, Winters R, Kerr R, Fritz M. Mandibular rescue: Application of the ALT fascia free flap to arrest osteoradionecrosis of the mandible. American journal of otolaryngology. 2019 Nov-Dec:40(6):102262. doi: 10.1016/j.amjoto.2019.07.006. Epub 2019 Jul 8 [PubMed PMID: 31351741]
Contrera KJ, Chinn SB, Weber RS, Roberts D, Myers JN, Lai SY, Lewis CM, Hessel AC, Gillenwater AM, Mulcahy CF, Yu P, Hanasono MM, Fuller CD, Chambers MS, Zafereo ME. Outcomes after definitive surgery for mandibular osteoradionecrosis. Head & neck. 2022 Jun:44(6):1313-1323. doi: 10.1002/hed.27024. Epub 2022 Mar 3 [PubMed PMID: 35238096]
Fritz MA, Arianpour K, Liu SW, Lamarre ED, Genther DJ, Ciolek PJ, Byrne PJ, Prendes BL. Managing Mandibular Osteoradionecrosis. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2025 Feb:172(2):406-418. doi: 10.1002/ohn.990. Epub 2024 Sep 27 [PubMed PMID: 39327863]
Corrao G, Mazzola GC, Lombardi N, Marvaso G, Pispero A, Baruzzi E, Decani S, Tarozzi M, Bergamaschi L, Lorubbio C, Repetti I, Starzyńska A, Alterio D, Ansarin M, Orecchia R, D'Amore F, Franchini R, Nicali A, Castellarin P, Sardella A, Lodi G, Varoni EM, Jereczek-Fossa BA. Oral Surgery and Osteoradionecrosis in Patients Undergoing Head and Neck Radiation Therapy: An Update of the Current Literature. Biomedicines. 2023 Dec 18:11(12):. doi: 10.3390/biomedicines11123339. Epub 2023 Dec 18 [PubMed PMID: 38137559]
Forner LE, Dieleman FJ, Shaw RJ, Kanatas A, Butterworth CJ, Kjeller G, Alsner J, Overgaard J, Hillerup S, Hyldegaard O, Arnell P, von Buchwald C, Kaanders JHAM, Smeele LE, Specht L, Johansen J, Witjes MJH, Merkx MAW, Jansen EC. Hyperbaric oxygen treatment of mandibular osteoradionecrosis: Combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2022 Jan:166():137-144. doi: 10.1016/j.radonc.2021.11.021. Epub 2021 Nov 26 [PubMed PMID: 34843843]
Level 1 (high-level) evidenceChronopoulos A, Zarra T, Ehrenfeld M, Otto S. Osteoradionecrosis of the jaws: definition, epidemiology, staging and clinical and radiological findings. A concise review. International dental journal. 2018 Feb:68(1):22-30. doi: 10.1111/idj.12318. Epub 2017 Jun 25 [PubMed PMID: 28649774]
Tufano-Sugarman AM, Wang KY, Kohn N, Ghaly M, Parashar B, Frank D, Kamdar D, Pereira L, Fantasia J, Seetharamu N. Osteoradionecrosis versus Cancer Recurrence: An Unresolved Clinical Dilemma. ORL; journal for oto-rhino-laryngology and its related specialties. 2023:85(1):28-35. doi: 10.1159/000527261. Epub 2022 Dec 1 [PubMed PMID: 36455537]
Löfstrand J, Nyberg M, Karlsson T, Thórarinsson A, Kjeller G, Lidén M, Fröjd V. Quality of Life after Free Fibula Flap Reconstruction of Segmental Mandibular Defects. Journal of reconstructive microsurgery. 2018 Feb:34(2):108-120. doi: 10.1055/s-0037-1606537. Epub 2017 Sep 13 [PubMed PMID: 28905342]
Level 2 (mid-level) evidence